Synchronous Fluorescence Method for Determination of Bevacizumab and Fluorouracil in Laboratory Prepared Mixture, Pharmaceutical Dosage Forms and Spiked Plasma

Abstract Bevacizumab (BVC) is commonly co-administered with 5-fluorouracil (FLO) as a highly successful treatment for colon cancer. In this study, two spectrofluorimetric techniques were combined to provide an approach for concurrent quantification of BVC and FLO that is very sensitive, quick, easy and accurate. The inclusion of Tween-80 micellar system increased the native fluorescence intensity values of BVC and FLO, while the second derivative of the synchronous fluorescence intensity of the cited drugs at Δλ=100 nm allowed the concurrent estimation of cited drugs. The effect of various experimental conditions on the synchronous fluorescence of cited drugs were extensively examined to optimize them. The second derivative synchronous fluorimetry peak amplitudes for BVC and FLO were recorded at 450 nm and 440 nm, respectively. At a range of 100–1100 and 100–600 ng mL−1, the fluorescence-concentration graphs were built, with smaller quantification limits of 60.0 and 70.0 ng mL−1 and detection limits of 20.0 and 23.0 ng mL−1 for BVC and FLO, respectively. Without any major interference, the technique was effectively used to determine the cited drugs in raw material along with pharmaceutical formulations. The proposed technique was shown to be extremely precise and accurate when related to the reported techniques statistically. GRAPHICAL ABSTRACT